{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypercalcaemia/management/follow-up-in-primary-care/","result":{"pageContext":{"chapter":{"id":"fb65182a-1069-5bbd-9c43-a547a8632cec","slug":"follow-up-in-primary-care","fullItemName":"Scenario: Follow-up in primary care","depth":2,"htmlHeader":"<!-- begin field 78696dc9-a507-4f7d-9dcc-aa8400f3c08f --><h2>Scenario: Follow-up in primary care</h2><!-- end field 78696dc9-a507-4f7d-9dcc-aa8400f3c08f -->","summary":"Covers the monitoring and follow-up of people with hypercalcaemia who have not undergone curative parathyroid surgery, or people with hypercalcaemia of malignancy.","htmlStringContent":"<!-- begin item ce0f73ad-3a90-4343-a82b-aa8400f3c032 --><!-- begin field 072b75a7-20b5-483c-84b8-acbc0155cd41 --><p>From age 18 years onwards.</p><!-- end field 072b75a7-20b5-483c-84b8-acbc0155cd41 --><!-- end item ce0f73ad-3a90-4343-a82b-aa8400f3c032 -->","topic":{"id":"c0ab4dd9-cccf-54af-a952-765aa048de1d","topicId":"897bf773-43ef-4092-a798-d9eb4cbcb9cc","topicName":"Hypercalcaemia","slug":"hypercalcaemia","lastRevised":"Last revised in August 2019","chapters":[{"id":"dfffab44-62c8-5590-8bad-e41f249a89e7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"fbfb541d-eae2-5916-af42-b77d9c9ab401","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"3c7aba33-da1a-580a-b896-fb6026eb2ad8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61d715de-b85d-534b-8c6f-0cf5f59814c2","slug":"changes","fullItemName":"Changes"},{"id":"48c69505-e62a-5332-a3ad-fd44bb64bd34","slug":"update","fullItemName":"Update"}]},{"id":"0105d032-866a-57c0-8c83-2f54f2b7b491","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"989b5402-77d7-5cd9-86a7-979019eba917","slug":"goals","fullItemName":"Goals"},{"id":"5d8d7c84-01cb-59e9-a02e-489cb32e799e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e7c39bf4-b50f-51f7-ad27-49c431acf456","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1bb69f34-e184-554d-a518-e9d59c4f95de","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d7060151-5501-51fc-b393-844af2c2ca54","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7d4d8cad-82f7-5bb5-8c59-b47873b845b2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4408b725-f01f-596c-b319-5ef7dd246c3c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"28f41cc2-0513-5841-9fa6-1a59bb557452","slug":"definition","fullItemName":"Definition"},{"id":"b1dd3a7e-6be5-523b-a2c5-c41f9b364798","slug":"causes","fullItemName":"Causes"},{"id":"048198e1-607a-55c4-9d7d-a63135379c28","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3c5e2134-d0b1-5804-bc33-86db97dfc33b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"62c64451-7e13-5be6-b868-01f8198a13ac","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dc0291c2-c628-503e-a7f7-7f3fa1362b62","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c5771a8e-2f1e-53ad-a2fc-322152fc3a3e","slug":"confirmation","fullItemName":"Confirmation"},{"id":"44ef7f17-c907-5252-8027-300e87635dc4","slug":"assessment","fullItemName":"Assessment"}]},{"id":"d005c3ba-c691-53c3-b23c-1c70928fb05d","fullItemName":"Management","slug":"management","subChapters":[{"id":"c604ea66-1be5-51cc-b014-9af770bbc709","slug":"unconfirmed-cause","fullItemName":"Scenario: Unconfirmed cause"},{"id":"4863d234-7059-57aa-b9cc-a51e3a1f3424","slug":"known-malignancy","fullItemName":"Scenario: Known malignancy"},{"id":"fb65182a-1069-5bbd-9c43-a547a8632cec","slug":"follow-up-in-primary-care","fullItemName":"Scenario: Follow-up in primary care"}]},{"id":"4017390d-3b38-5741-8d16-22624da35f3d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2ec3d6b5-1818-5b5f-af66-bd097d709bf2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"847bb207-2cb8-5e5f-b3e8-ee87440a71cd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"47a9d106-98da-5683-9641-88d123a8d071","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a8225b5a-40b4-53e5-9095-0953daa376fa","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c60f947f-6176-53b3-9484-54b966632a77","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"b6a6af13-45f8-5258-a611-6d8306bbe251","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f68489fb-5d5f-5342-94a0-3979f632012b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d005c3ba-c691-53c3-b23c-1c70928fb05d","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"27630856-65e9-513a-984c-bcad0fc2ca6b","slug":"follow-up","fullItemName":"Follow-up","depth":3,"htmlHeader":"<!-- begin field dc7f75ce-31bc-4f15-95e7-aa8400f3c095 --><h3>Follow-up in primary care</h3><!-- end field dc7f75ce-31bc-4f15-95e7-aa8400f3c095 -->","summary":null,"htmlStringContent":"<!-- begin item 83a48ad5-ffe9-489f-82c8-aa8400f3c095 --><!-- begin field fe9c2a3b-8fca-4d59-81de-aa8400f3c095 --><p><strong>Arrange appropriate monitoring and follow-up in primary care depending on specialist advice.</strong></p><ul><li><strong>If a person has a confirmed diagnosis of asymptomatic <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/causes/\">primary hyperparathyroidism</a> (or if parathyroid surgery is <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/management/unconfirmed-cause/#specialist-assessment-management\">not appropriate</a>):</strong><ul><li>Provide advice on sources of information and support, such as:<ul><li>The NHS information leaflet <a data-hyperlink-id=\"f4a5ee35-46a9-4322-88fb-aa9b012aa909\" href=\"https://www.nhs.uk/conditions/hyperparathyroidism/\" target=\"_blank\">Hyperparathyroidism</a>.</li></ul></li><li>Monitor for <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/diagnosis/diagnosis/\">symptoms</a> of hypercalcaemia.</li><li>Arrange monitoring of serum calcium, estimated glomerular filtration rate (eGFR) and creatinine every 12 months.</li><li>Monitor bone mineral density by dual-energy X-ray absorptiometry (DEXA) every 2–3 years, depending on specialist advice.</li><li>Arrange X-ray or vertebral fracture assessment of the spine if clinically indicated, for example if there is height loss and/or back pain. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a> for more information.</li><li>Arrange renal imaging such as ultrasound, X-ray, or CT if renal stones are suspected. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/renal-or-ureteric-colic-acute/\">Renal or ureteric colic - acute</a> for more information.</li><li>Arrange a cardiovascular risk assessment. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> for more information.</li></ul></li><li><strong>If a person has asymptomatic primary hyperparathyroidism, arrange re-referral to an endocrinology specialist if:</strong><ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/diagnosis/diagnosis/\">Symptoms</a> of hypercalcaemia develop.</li><li>The adjusted serum calcium concentration increases to 0.25 mmol/L or more above the normal range. Note: the National Institute for Health and Care Excellence (NICE) recommends an adjusted serum calcium level of 2.85 mmol/L or above.</li><li>The eGFR is less than 60 mL/min/1.73 m<sup>2</sup>. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a> for more information.</li><li>There are renal stones or increased risk of renal stones (for example following urinary biochemical <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/management/unconfirmed-cause/#specialist-assessment-management\">stone risk analysis</a>).</li><li>There is osteoporosis confirmed on DEXA, or if a vertebral or other fragility fracture occurs. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a> for more information.</li></ul></li><li><strong>If a person has known <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/causes/\">malignancy-associated</a> hypercalcaemia:</strong><ul><li>Provide advice on sources of information and support, such as:<ul><li>The national charity Cancer Research UK (website <a data-hyperlink-id=\"44ada7cc-d39a-4fac-b026-aaa000eec374\" href=\"https://www.cancerresearchuk.org/\" target=\"_blank\">www.cancerresearchuk.org</a>) patient information <a data-hyperlink-id=\"5f094e2a-6f7f-4d90-b65d-aaa000eec394\" href=\"https://www.cancerresearchuk.org/about-cancer/coping/physically/blood-calcium\" target=\"_blank\">Cancer and blood calcium levels</a>.</li></ul></li><li>Monitor for <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/diagnosis/diagnosis/\">symptoms</a> of hypercalcaemia.</li><li>Arrange monitoring of serum calcium, estimated glomerular filtration rate (eGFR) and creatinine, the frequency depending on specialist advice or clinical judgement.<ul><li>If the underlying cancer is not actively treated, hypercalcaemia usually returns 2–4 weeks after calcium-lowering treatment.</li></ul></li><li>Liaise with the person's oncologist or palliative care specialist if there is any uncertainty about ongoing management and monitoring. See the Scenario on <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/management/follow-up-in-primary-care/\">Follow-up in primary care</a> for more information.</li></ul></li><li><strong>For all people, offer advice on general lifestyle measures:</strong><ul><li>Ensure the person maintains adequate hydration provided there are no contraindications (such as severe kidney disease or heart failure).</li><li>Ensure the person is vitamin D replete. Vitamin D supplementation should be given with caution, and will usually be arranged by the person's specialist. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/\">Vitamin D deficiency in adults - treatment and prevention</a> for more information.</li><li>Ensure the person has sufficient dietary calcium intake. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/\">Vitamin D deficiency in adults - treatment and prevention</a> for more information on how to calculate dietary calcium intake.</li><li>Encourage mobilization where possible, to avoid exacerbating hypercalcaemia, especially where <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/causes/\">immobilization</a> is a contributory factor.</li><li>Avoid any <a class=\"topic-reference internal-reference\" href=\"/topics/hypercalcaemia/background-information/causes/\">drugs</a> or supplements that can cause or worsen hypercalcaemia.</li></ul></li></ul><!-- end field fe9c2a3b-8fca-4d59-81de-aa8400f3c095 --><!-- end item 83a48ad5-ffe9-489f-82c8-aa8400f3c095 -->","subChapters":[{"id":"6c96a893-a186-5e75-acdd-ca5e5d26f35e","slug":"basis-for-recommendation-219","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 98872d49-c937-41c5-951c-aa8400f3c097 --><h4>Basis for recommendation</h4><!-- end field 98872d49-c937-41c5-951c-aa8400f3c097 -->","summary":null,"htmlStringContent":"<!-- begin item 21907ee2-cbca-4452-b61e-aa8400f3c097 --><!-- begin field a9716c81-2130-4e95-97bc-aa8400f3c097 --><p>The recommendations on follow-up in primary care are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Hyperparathyroidism (primary): diagnosis, assessment and initial management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>], the international consensus documents <em>Medical management of primary hyperparathyroidism: proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Marcocci et al, 2013</a>], <em>Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian et al, 2014</a>], and <em>Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Eastell et al, 2014</a>]; and expert opinion in review articles on hypercalaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>], on parathyroid disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Insogna, 2018</a>], on hypercalcaemia of malignancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Seccareccia, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>], and in a palliative care textbook <em>A guide to symptom relief in palliative care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Regnard, 2010</a>].</p><h5>Follow-up of asymptomatic primary hyperparathyroidism (or if parathyroid surgery is inappropriate)</h5><ul><li>The recommendation to provide sources of information and support is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>].</li><li>The recommendations on the frequency and type of blood test monitoring in primary care is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>], and expert opinion in the international consensus document on asymptomatic primary hyperparathyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian et al, 2014</a>] and in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Pallan et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian, 2018</a>].<ul><li>The NICE guideline committee agreed that the risk of recurrent primary hyperparathyroidism after successful parathyroid surgery is very low, and therefore annual monitoring of adjusted serum calcium levels is sufficient, based on their knowledge and experience.</li></ul></li><li>The recommendations on the frequency of bone mineral density monitoring, assessment for suspected vertebral fracture, and when renal imaging is needed in primary care are largely based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>]. CKS notes that the international consensus document on asymptomatic primary hyperparathyroidism recommends checking bone mineral density every 1–2 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian et al, 2014</a>]. This is supported by expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Turner, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian, 2018</a>].</li><li>The recommendation to arrange a cardiovascular risk assessment is based on the NICE clinical guideline which recommends this approach for all people with primary hyperparathyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>].</li></ul><h5>Criteria for re-referral to an endocrinology specialist</h5><ul><li>The recommendations on when to re-refer to endocrinology are based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>] and the international consensus document on asymptomatic primary hyperparathyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian et al, 2014</a>].</li></ul><h5>Follow-up of malignancy-associated hypercalcaemia</h5><ul><li>The information that without treatment of the underlying malignancy, hypercalcaemia usually returns 2–4 weeks after calcium-lowering treatment is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Seccareccia, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>] and in a palliative care textbook<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Regnard, 2010</a>].</li><li>The recommendation to liaise with the person's oncologist or palliative care specialist if there is any uncertainty about ongoing management is based on expert opinion in a review article that treatment of the underlying malignancy may improve hypercalcaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>].</li></ul><h5>Advice on general lifestyle measures</h5><ul><li>The recommendation to ensure adequate hydration is based on the fact that dehydration limits the kidney's ability to excrete calcium which may worsen hypercalcaemia, and it may increase the risk of renal stone formation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Clines, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Insogna, 2018</a>]. The recommendation to avoid volume overload is extrapolated from expert opinion in a review article, which notes that this is particularly relevant for people with renal impairment or heart failure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Zagzag, 2018</a>].</li><li>The recommendation to ensure adequate vitamin D is based on the international consensus documents [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Marcocci et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Eastell et al, 2014</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Insogna, 2018</a>], as people with vitamin D insufficiency or deficiency are at risk of more severe primary hyperparathyroidism. The information that vitamin D supplementation is usually arranged by the person's specialist is based on the NICE clinical guideline on primary hyperparathyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">NICE, 2019</a>].</li><li>The recommendation to ensure adequate dietary calcium intake is based on the fact that a low calcium diet may conversely stimulate parathyroid hormone (PTH) secretion, increase intestinal calcium absorption, and worsen hypercalcaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Marcocci et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Bilezikian, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Insogna, 2018</a>].</li><li>The recommendation to encourage mobilization is extrapolated from the fact that this should reduce the risk of bone resorption and hypercalcaemia resulting from inactivity and bed rest [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Meng, 2015</a>] .</li><li>The recommendation to advise the person to avoid drugs or supplements that can worsen hypercalcaemia is based on expert opinion from a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercalcaemia/references/\">Minisola, 2015</a>].</li></ul><!-- end field a9716c81-2130-4e95-97bc-aa8400f3c097 --><!-- end item 21907ee2-cbca-4452-b61e-aa8400f3c097 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}